Stephen Hoge - 01 Mar 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
01 Mar 2022
Net transactions value
-$1,484,500
Form type
4
Filing time
03 Mar 2022, 15:56:31 UTC
Previous filing
25 Feb 2022
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $9,900 +10,000 +0.62% $0.9900* 1,620,791 02 Mar 2022 Direct F1
transaction MRNA Common Stock Sale $1,494,400 -10,000 -0.62% $149.44 1,610,791 02 Mar 2022 Direct F1
holding MRNA Common Stock 4,116 01 Mar 2022 By Valhalla, LLC
holding MRNA Common Stock 151,933 01 Mar 2022 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +42,282 $0.000000 42,282 01 Mar 2022 Common Stock 42,282 $149.52 Direct F3
transaction MRNA Restricted Stock Units Award $0 +10,425 $0.000000 10,425 01 Mar 2022 Common Stock 10,425 $0.000000 Direct F4
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10,000 -8.5% $0.000000 107,431 02 Mar 2022 Common Stock 10,000 $0.9900 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
F2 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F3 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 This option is fully vested and exercisable.